Safety monitoring and interim analysis
Since both cardioplegia solutions are already in use and FDA-approved, there are no safety concerns at the time being. However, an interim analysis will be carried out every 6 months, and the principal investigator will decide whether to stop or carry on if any major discrepancies in outcomes are observed.